

Enhanced online provider search and directory now available

Applies to: All participating providers

Plan(s): All

We have recently upgraded our [online provider search function](#) with new features that improve navigation and search capabilities—making it easier for members to get connected to the providers they need.

We encourage you to use the new provider search function to ensure the information we have for you on file is accurate. Visit us at geisinger.org/health-plan or the GHP plan central page on NaviNet.net and choose *Find a doctor or location* to access the search page and review your information. If you need to update your information, use the [practice information change form](#) available in the *For Providers* section of the GHP website and the *Resources* section of [NaviNet](http://NaviNet.net). Complete the form and submit it to GHP. Changes you indicate on the form will be verified and updated in our provider database, which feeds the data displayed in the online directory.

2019 Geisinger Gold overview

Applies to: All participating providers

Plan(s): Geisinger Gold

Geisinger Gold serves more than 94,000 members in 43 counties throughout Pennsylvania. Geisinger Gold is contracted with more than 125 area hospitals, 33,000 plus providers and nearly 3,000 pharmacies in Pennsylvania to provide medical care for members.

The annual election period for Medicare enrollees runs from Oct. 15 through Dec. 7, 2018.

Check out the [2019 plan overview](#) to familiarize yourself with the 2019 plan offerings and the benefit changes your existing Geisinger Gold patients can expect to encounter.

Contents

Enhanced provider search	1
2019 Geisinger Gold overview	1
Home testing kits for Gold	2
Podiatry coding for E&M services	2
Gold pharmacy changes	2
Lead testing in Carbon county	3
PROMISE™ ID needed for CHIP	3
Update your PROMISE™ account	3
Synagis® for in-home use	4
Medical policy update	6
Medical pharmaceutical policy updates	7

Geisinger Health Plan (GHP) may refer collectively to Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted.

HPM50 GHP MPU Oct 2018

Helping your patients complete important screenings: Geisinger Gold members to receive home testing kits

Applies to: All participating providers

Plan(s): Geisinger Gold

GHP has teamed with BioIQ, an independent healthcare technology company, to help your patients take proactive steps in getting important health screenings. This year, we are offering Gold members home testing kits for A1C, microalbumin and OC-Auto FIT screenings. Gold members who are non-compliant for a combination of these screenings will receive the tests in separately mailed kits.

We will offer the at-home test kits to approximately 15,000 Gold members. There is no extra cost for these tests to either you or your patients. When your patients complete the tests at home and return the kits to the BioIQ lab for analysis, both you and your patients receive the lab results from BioIQ. Your patients will receive a note telling them to contact you to discuss those results.

More information on BioIQ is available on the GHP plan central page at NaviNet.net. If you have questions regarding your Gold patients and BioIQ home testing kits, contact 866-847-1216, 8 a.m. – 4:30 p.m., Monday through Friday.

Podiatry coding for E&M services

Applies to: Podiatry providers

Plan(s): GHP Family

Effective Aug. 1, 2018, evaluation and management codes for podiatrists were removed from the Medicaid fee schedule. These codes are now only payable when billed with an appropriate modifier. Podiatrists should refer to the [Medicaid fee schedule online](#) to verify E&M codes and modifier billing guidelines.



Important pharmacy changes for Geisinger Gold members

Applies to: All participating providers

Plan(s): Geisinger Gold

Two network or formulary changes will affect Geisinger Gold members, starting Jan. 1, 2019.

- Walgreen's Pharmacy has decided to leave the Geisinger Gold pharmacy network. Starting Jan.1, 2019, Walgreens Pharmacy will no longer accept Geisinger Gold insurance.
- Geisinger Gold will no longer cover Januvia, Janumet, or Janumet XR for Geisinger Gold members. Similar medications Tradjenta, Jentadueto, and Jentadueto XR continue to be covered for Geisinger Gold members without prior authorization. If you feel a patient should continue to take Januvia, Janumet or Janumet XR, request prior authorization for this medicine by faxing a prior authorization request form to GHP at 570-271-5610 or use the GHP PromptPA portal at ghp.promptpa.com.

If you have any questions, call the Geisinger Health Plan pharmacy department at 800-988-4861, 8:00 a.m. – 8:00 p.m., seven days a week.

Elevated risk of lead exposure in Palmerton, Carbon county

Applies to: All providers serving residents of Palmerton, Carbon county Plan(s): GHP Family

The Department of Human Services — in support of the efforts of the Pennsylvania Departments of Health and of Environmental Protection — want residents and healthcare providers in the Palmerton area to be aware of increased environmental lead hazards from the American Zinc Recycling (AZR) facility, formerly known as Horsehead Corporation. The facility has been a Superfund site, where federal and state oversight is involved in cleanup since 1983 due to contamination related to former zinc smelting operations. A recent [federal study](#) examined the Palmerton community's potential exposure to lead. The study concludes that young children and pregnant women living near the AZR facility are likely at higher risk for elevated blood-lead levels.

All GHP Family children are considered at risk for lead toxicity. Risk questions should be asked at every visit. Lead screening is required at age 9 – 11 months. If not completed during that time, it must be done at the next screening opportunity of 12, 15 or 18 months and again at 24 months. If not completed at 24 months, it must be done at the next screening opportunity of 30 months, 3, 4, 5 or 6 years. Procedure code 83655 (lead testing) is used with the EP modifier. GHP Family members with blood lead levels greater than 10 µg/dL need to be referred to GHP's Special Needs Unit (SNU) to coordinate environmental testing by a contracted vendor. Providers may refer patients directly by contacting the SNU at 855-214-8100. Please inform the SNU that the referral is for an elevated blood lead level of 10 µg/dL or greater.

PROMISe™ ID needed to see CHIP and GHP Kids patients

Applies to: All participating providers Plan(s): GHP Kids

DHS regulations require that you must enroll with the Pennsylvania Department of Human Services (DHS) as soon as possible to continue seeing GHP Kids and other Children's Health Insurance Program (CHIP) enrollees. We encourage you to enroll immediately to minimize any disruption to your GHP Kids patients. Providers not registered with DHS at each service location risk delayed processing and/or denial of claims.

DHS has implemented Affordable Care Act (ACA) provisions requiring all providers and other practitioners who render, order, refer or prescribe items or services to CHIP enrollees be enrolled with DHS as a provider. You must complete an enrollment application for

your provider type for each service location (provider's address) and submit all required documents to DHS. All applications, requirements and the step-by-step instructions are available at [CHIP Provider Enrollment Information on the DHS website](#).

Update your information in PROMISe™ today

Applies to: All participating providers Plan(s): GHP Family and GHP Kids

Any and all practitioners who render, order, refer or prescribe items or services for MA and CHIP beneficiaries, are required to have a PROMISe ID registered with the Pennsylvania Department of Human Services (DHS). If you are currently enrolled, you are responsible for keeping your information current with the state through the [PROMISe portal](#). Login to the PROMISe portal today to make sure your provider profile on record with the state is accurate.

Synagis® for in-home use through US Bioservices

Applies to: Participating PCPs and pediatricians Plan(s): All plans

GHP has contracted with US Bioservices as a Synagis® provider for in-home use. US Bioservices has been supporting Synagis® patients and families for over 15 years and is deemed a respiratory syncytial virus (RSV) Center of Excellence. The Synagis® team provides comprehensive care coordination, including:

- Nursing visits scheduled with pediatric nurses
- Clinical assessment calls before and after dispensing
- Verified weight-based dosing on each fill
- 24/7 clinical support provided by pharmacists and nurses
- Medication delivery to the patients designated site of care
- RSV/Synagis education and dose appointment reminders

These services offer support and efficiency, leading to improved outcomes and compliance for the patient.

US Bioservices also works with the prescribing provider by offering:

- Assistance with prior authorization
- Specialized treatment coordination, which includes proactive, collaborative communication with the prescribing physician office
- Tracking insurance authorizations to prevent gaps in therapy
- MyPathpoint Prescriber Portal, an application that shows the status of a prescription from receipt to delivery



Synagis® requires prior authorization by GHP. No additional prior authorization is needed for at-home use. Physicians prescribing Synagis® for their patients will receive information on US Bioservices upon authorization approval. You may also contact the GHP medical management department for information at 800-544-3907. Visit the US Bioservices website at usbioservices.com or call the dedicated Synagis® department at 877-872-4604 for more information on the home use program.

Medicare health outcomes survey — Improving or maintaining mental health

The Medicare Health Outcomes Survey (HOS) is used to gather clinically meaningful data from Medicare Advantage beneficiaries. The survey is used to gauge plan performance, inform Medicare Advantage beneficiaries' healthcare choices and advance research into population health. All managed care organizations with Medicare contracts, including Geisinger Gold, must participate.

Although most cases of depression are diagnosed in younger adults, it's just as important for an older person with symptoms of depression to seek treatment. Depression can worsen health in people with conditions like heart disease, diabetes, and stroke. Depression can also complicate treatment for these conditions.

The percentage of patients whose mental health was the same or better than expected after two years is measured by HOS. You can help improve and maintain your aging and elderly patients' mental health by doing the following:

- Routinely assess your patient's emotional problems, depression, anxiety and addictions. Determine how these affect their daily life and social interactions.
- Provide referrals for behavioral health services, depression management services and treatment centers.
- Integrate motivational interviewing to improve treatment engagement and mental health outcomes.

For comprehensive information about the Medicare Health Outcomes Survey program, visit the CMS HOS website at <http://hosonline.org>.



Get your claims question answered faster with secure messaging on NaviNet

Look for the Secure Messaging tab under Workflows for this Plan on NaviNet.net. Include the claim number(s) in the subject line and add your comments. Your message will go directly to the GHP claims and reimbursement team for review and response to you via NaviNet.

Formulary and policy updates

Visit Geisinger Health Plan on NaviNet.net today to view new, revised and recently reviewed medical and pharmaceutical policies, as well as the latest clinical guidelines, formulary changes and drug recalls. Updates may affect prior authorization. The most current prior authorization list is also available on NaviNet.net. Clinical guidelines, formulary and medical policy information are also available in the “For Providers” section at GeisingerHealthPlan.com. Printed copies are available upon request.

Medical policy update

GHP uses medical policies as guidelines for coverage decisions made within the insured individuals written benefit documents. Coverage may vary by line of business. Providers and members are encouraged to verify benefit questions regarding eligibility before applying the terms of the policy. [Click here for updates](#). **The new and revised medical policies listed below go into effect Nov. 15, 2018:**

- MP148 Ambulatory Cardiac Event Monitors – REVISED (added exclusions)
- MP053 Cochlear Implant – REVISED (added indications)
- MP059 Fetal Surgery – REVISED – (added indication)
- MP239 Pharmacogenetic Testing for Warfarin Metabolism – REVISED – (added indication and exclusions)
- MP296 Occipital Nerve Block – REVISED – (removed prior auth)
- MP322 Drug Testing in Substance Abuse Treatment – NEW POLICY

The following policies have been reviewed with no change to the policy section. Additional references or background information was added to support the current policy.

- MP024 External Counterpulsation
- MP069 Ultrafiltration
- MP080 Cardiac Rehab
- MP115 Autologous Chondrocyte Implant
- MP116 Hippotherapy
- MP117 Dry Hydrotherapy
- MP118 Quantitative Sensory Testing
- MP120 Intracavitary Balloon Brachytherapy for Breast Cancer
- MP161 Thermal Capsulorrhaphy
- MP166 MR Ultrasound Ablation of Uterine Fibroids
- MP181 Suit Therapy
- MP274 Diapers and Incontinence Supplies
- MP284 Bone Mineral Density Measurement
- MP302 Percutaneous Tibial Nerve Stimulation

GHP continues to solicit physician and non-physician provider input concerning medical policies.

Your feedback is encouraged and appreciated. Comments should be sent to Phillip Krebs at pkrebs@thehealthplan.com.

Formulary and policy updates

Medical pharmaceutical policy updates

The new and revised medical pharmaceutical policies listed below go into effect Nov. 15, 2018:

- MBP 4.0 Intravenous Immune Globulin (IVIG) – REVISED
- MBP 53.0 Eraxis (anidulafungin) – REVISED

The following policies have been reviewed with no change to the policy section.

- MBP 7.0 Aldurazyme (laronidase)
- MBP 18.0 Fabrazyme (agalsidase beta)
- MBP 23.0 Velcade (bortezomib)
- MBP 29.0 Elitek (rasburicase)
- MBP 38.0 Clolar (clofarabine)
- MBP 50.0 Vectibix (panitumumab)
- MBP 76.0 Actemra IV (tocilizumab)
- MBP 78.0 Istodax (romidepsin)
- MBP 80.0 Xiaflex (collagenase clostridium histolyticum)
- MBP 106.0 Injectable Antipsychotic Medications
- MBP 110.0 Xofigo (radium Ra 223 dichloride)
- MBP 114.0 Vimizim (elosulfase alfa)
- MBP 120.0 Sylvant (siltuximab)
- MBP 121.0 Dalvance (dalbavancin)
- MBP 122.0 Sivextro (tedizolid phosphate) IV
- MBP 136.0 Imlygic (talimogene laherparepvec)
- MBP 137.0 Yondelis (trabectedin)
- MBP 138.0 Onivyde (irinotecan liposome injection)
- MBP 140.0 Empliciti (elotuzumab)
- MBP 152.0 Bavencio (avelumab)
- MBP 155.0 Ocrevus (ocrelizumab)
- MBP 157.0 Brineura (cerliponase alfa)

For questions regarding drug benefits call 800-988-4861, 8:00 a.m. to 5:00 p.m., Monday through Friday.

